Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent subunit influenza vaccine
- Development stage
- Unknown
- Lead developer
- Ab&B Bio-tech Co., Ltd.
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Trivalent subunit influenza vaccines are a type of inactivated influenza vaccine that contains purified hemagglutinin (HA) and neuraminidase (NA) antigenic proteins from three influenza virus strains: one influenza A(H1N1) virus, one influenza A(H3N2) virus, and one influenza B virus (typically from the Victoria lineage). These vaccines are prepared by further extracting, purifying, and concentrating the HA and NA proteins from split-virion vaccines. The subunit formulation reduces reactogenicity compared to whole-virus vaccines while maintaining immunogenicity in primed populations. Starting with the 2024-2025 flu season, all influenza vaccines in the United States have transitioned from quadrivalent to trivalent formulations due to the apparent disappearance of the B/Yamagata lineage viruses since March 2020.
- Brand names
- Influvac
- Other names
- trivalent sub-unit influenza vaccine
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on trivalent subunit influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent subunit influenza vaccine.